Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood hodgkin disease

Stoneham, Sara, Ashley, Sue, Pinkerton, C. Ross, Wallace, W. Hamish and Shankar, Ananth Gouri (2004) Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood hodgkin disease. Journal of Pediatric Hematology Oncology, 26 11: 740-745. doi:10.1097/00043426-200411000-00010

Author Stoneham, Sara
Ashley, Sue
Pinkerton, C. Ross
Wallace, W. Hamish
Shankar, Ananth Gouri
Title Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood hodgkin disease
Journal name Journal of Pediatric Hematology Oncology   Check publisher's open access policy
ISSN 1077-4114
Publication date 2004-11
Sub-type Article (original research)
DOI 10.1097/00043426-200411000-00010
Volume 26
Issue 11
Start page 740
End page 745
Total pages 6
Place of publication New York, United States
Publisher Lippincott Willams & Wilkins
Language eng
Subject 1102 Cardiovascular Medicine and Haematology
Formatted abstract
Objectives: To determine the clinical outcome and prognostic factors for overall survival in children with recurrent and/or primary refractory Hodgkin disease (HD) after high-dose therapy and autologous hemopoietic stem cell transplantation (AHSCT). The survival outcome of this treatment was compared with conventional salvage therapy without stem cell transplantation.

Methods: Clinical records of 51 patients with relapsed or refractory HD who underwent AHSCT were reviewed. The source of the stem cells was bone marrow (n = 22) or peripheral blood (n = 29). At the time of high-dose therapy, 39 patients were in complete remission and 1 was in partial remission, while the remaining 11 had refractory disease. The records of 78 patients from the HD 1 trial who underwent conventional salvage treatment but without AHSCT for relapsed or refractory HD were also reviewed. All patients received HDTwithout radiation for conditioning.

Results: Overall survival from diagnosis of patients treated with AHSCT did not differ significantly from that of those treated with conventional salvage therapy (hazard ratio = 1.5; 95% confidence interval = 0.9-8.2; P = 0.4). There were also no statistically significant differences in survival data between the two approaches for patients whose duration of first remission was less than or greater than 1 year (P = 0.5; stratified log-rank). Of the 11 patients who received AHSCT for refractory disease, 9 remain alive and well with followups ranging from 2 to 18 years. No deaths due to treatment-related complications were seen in the AHSCT group.

Conclusions: Stem cell transplantation does not offer any significant survival advantage over conventional salvage therapy in children with relapsed HD, although it may be of benefit for patients with primary refractory disease.
Keyword Prognostic factors
Hodgkin disease
Autologous hemopoietic stem cell transplantation
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 20 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 25 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 13 Jan 2010, 15:08:30 EST by Simon Utteridge on behalf of Faculty Of Health Sciences